328 related articles for article (PubMed ID: 26745765)
1. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium.
Miller BE; Tal-Singer R; Rennard SI; Furtwaengler A; Leidy N; Lowings M; Martin UJ; Martin TR; Merrill DD; Snyder J; Walsh J; Mannino DM
Am J Respir Crit Care Med; 2016 Mar; 193(6):607-13. PubMed ID: 26745765
[TBL] [Abstract][Full Text] [Related]
2. The COPD Biomarker Qualification Consortium (CBQC).
Casaburi R; Celli B; Crapo J; Criner G; Croxton T; Gaw A; Jones P; Kline-Leidy N; Lomas DA; Merrill D; Polkey M; Rennard S; Sciurba F; Tal-Singer R; Stockley R; Turino G; Vestbo J; Walsh J
COPD; 2013 Jun; 10(3):367-77. PubMed ID: 23713597
[TBL] [Abstract][Full Text] [Related]
3. Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD.
Mannino DM; Tal-Singer R; Lomas DA; Vestbo J; Graham Barr R; Tetzlaff K; Lowings M; Rennard SI; Snyder J; Goldman M; Martin UJ; Merrill D; Martin AL; Simeone JC; Fahrbach K; Murphy B; Leidy N; Miller B
Chronic Obstr Pulm Dis; 2015; 2(1):23-34. PubMed ID: 25685850
[TBL] [Abstract][Full Text] [Related]
4. Precision Medicine in Chronic Obstructive Pulmonary Disease.
Hurst JR
Am J Respir Crit Care Med; 2016 Mar; 193(6):593-4. PubMed ID: 26977962
[No Abstract] [Full Text] [Related]
5. Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort.
Rønnow SR; Sand JMB; Langholm LL; Manon-Jensen T; Karsdal MA; Tal-Singer R; Miller BE; Vestbo J; Leeming DJ
Respir Res; 2019 Apr; 20(1):63. PubMed ID: 30935391
[TBL] [Abstract][Full Text] [Related]
6. Biomarker qualification pilot process at the US Food and Drug Administration.
Goodsaid F; Frueh F
AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in chronic obstructive pulmonary disease.
Rosenberg SR; Kalhan R
Transl Res; 2012 Apr; 159(4):228-37. PubMed ID: 22424427
[TBL] [Abstract][Full Text] [Related]
8. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview.
Woodcock J; Buckman S; Goodsaid F; Walton MK; Zineh I
Expert Opin Med Diagn; 2011 Sep; 5(5):369-74. PubMed ID: 23484625
[TBL] [Abstract][Full Text] [Related]
9. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease.
Duvoix A; Dickens J; Haq I; Mannino D; Miller B; Tal-Singer R; Lomas DA
Thorax; 2013 Jul; 68(7):670-6. PubMed ID: 22744884
[TBL] [Abstract][Full Text] [Related]
10. Biomarker qualification via public-private partnerships.
Eck SL; Paul SM
Clin Pharmacol Ther; 2010 Jan; 87(1):21-3. PubMed ID: 20019697
[TBL] [Abstract][Full Text] [Related]
11. Building a roadmap to biomarker qualification: challenges and opportunities.
Amur SG; Sanyal S; Chakravarty AG; Noone MH; Kaiser J; McCune S; Buckman-Garner SY
Biomark Med; 2015; 9(11):1095-105. PubMed ID: 26526897
[TBL] [Abstract][Full Text] [Related]
12. Qualification of cardiac troponins for nonclinical use: a regulatory perspective.
Hausner EA; Hicks KA; Leighton JK; Szarfman A; Thompson AM; Harlow P
Regul Toxicol Pharmacol; 2013 Oct; 67(1):108-14. PubMed ID: 23876748
[TBL] [Abstract][Full Text] [Related]
13. Fibrinogen as a potential biomarker for clinical phenotype in patients with chronic obstructive pulmonary disease.
Kim TH; Oh DK; Oh YM; Lee SW; Do Lee S; Lee JS
J Thorac Dis; 2018 Sep; 10(9):5260-5268. PubMed ID: 30416773
[TBL] [Abstract][Full Text] [Related]
14. The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction.
Menetski JP; Hoffmann SC; Cush SS; Kamphaus TN; Austin CP; Herrling PL; Wagner JA
Clin Pharmacol Ther; 2019 Apr; 105(4):829-843. PubMed ID: 30648736
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of drug-induced acute kidney injury: a regulatory perspective.
Blank M; Thompson A; Hausner E; Rouse R
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):929-936. PubMed ID: 30099912
[TBL] [Abstract][Full Text] [Related]
16. Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice.
Mattes WB; Goodsaid F
Exp Biol Med (Maywood); 2018 Feb; 243(3):256-261. PubMed ID: 29110507
[TBL] [Abstract][Full Text] [Related]
17. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.
Amur S; LaVange L; Zineh I; Buckman-Garner S; Woodcock J
Clin Pharmacol Ther; 2015 Jul; 98(1):34-46. PubMed ID: 25868461
[TBL] [Abstract][Full Text] [Related]
18. Drug Development for Asthma and COPD: A Regulatory Perspective.
Mann M; Meyer RJ
Respir Care; 2018 Jun; 63(6):797-817. PubMed ID: 29794212
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort.
Mannino DM; Valvi D; Mullerova H; Tal-Singer R
COPD; 2012 Aug; 9(4):359-66. PubMed ID: 22489912
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen is a promising biomarker for chronic obstructive pulmonary disease: evidence from a meta-analysis.
Zhou B; Liu S; He D; Wang K; Wang Y; Yang T; Zhang Q; Zhang Z; Niu W
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
